Stefanie Urlinger

is VP of Biologics Discovery

Stefanie is an expert in antibody discovery and early antibody development.


Stefanie joined Ridgeline from iOmx Therapeutics, a German immuno-oncology biotech, where she was a member of the leadership team and led the antibody discovery efforts. Prior to iOmx Stefanie spent 16 years at MorphoSys, building and then heading MorphoSys’ internal discovery group. She was also responsible for the development of antibody platform technologies as well as therapeutic antibody programs.


Stefanie has authored 17 scientific articles and is an inventor on over 60 granted patents. She earned a Ph.D. at the Max-Planck-Institute for Biochemistry in Martinsried.

Getting in touch


Ridgeline Therapeutics GmbH
A Versant Ventures Discovery Engine

Aeschenvorstadt 36

CH 4051 Basel


Offices  and Labs

Ridgeline Therapeutics GmbH
Hochbergerstrasse 60C
CH 4057 Basel

A Versant Ventures Discovery Engine.




Imprint  /  Privacy Policy  /  Terms of Use

© 2018 Ridgeline Therapeutics GmbH,
Ridgeline Discovery GmbH